Alterations in the apoptotic machinery and their potential role in anticancer drug resistance - PubMed (original) (raw)
Review
. 2003 Oct 20;22(47):7414-30.
doi: 10.1038/sj.onc.1206945.
Affiliations
- PMID: 14576849
- DOI: 10.1038/sj.onc.1206945
Review
Alterations in the apoptotic machinery and their potential role in anticancer drug resistance
Scott H Kaufmann et al. Oncogene. 2003.
Abstract
Anticancer drugs can potentially kill cells in two fundamentally different ways, by interfering with cellular processes that are essential for maintenance of viability or by triggering an endogenous physiological cell death mechanism. Apoptosis is a form of physiological cell death mediated by caspases, a unique family of intracellular cysteine proteases. Zymogen forms of these proteases are found in virtually all somatic cells, but remain latent until their activation is induced by ligation of specific cell surface receptors (the so-called "death receptors"), by mitochondrial alterations that allow release of cytochrome c and other intermembrane components, or possibly by other mechanisms. Most anticancer drugs activate the mitochondrial pathway. This apoptotic pathway is regulated by pro- and antiapoptotic members of the Bcl-2 family of proteins. Once activated, certain caspases might also be controlled by the inhibitor of apoptosis (IAP) proteins. Alterations in apoptotic pathway components or their regulators have been detected in a variety of cancers, suggesting that loss of the ability of cells to undergo apoptosis might contribute to carcinogenesis. Because cancer therapies such as radiation, glucocorticoids, and chemotherapeutic drugs exert their beneficial effects, at least in part, by inducing apoptosis of cancer cells, the same alterations in apoptotic pathways would be predicted to contribute to resistance. A key issue is whether the direct toxic activity of these treatments is of benefit when neoplastic cells contain changes that diminish their ability to undergo apoptosis.
Similar articles
- IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs.
Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, Reed JC. Tamm I, et al. Cancer Res. 1998 Dec 1;58(23):5315-20. Cancer Res. 1998. PMID: 9850056 - Overcoming resistance of cancer cells to apoptosis.
Hersey P, Zhang XD. Hersey P, et al. J Cell Physiol. 2003 Jul;196(1):9-18. doi: 10.1002/jcp.10256. J Cell Physiol. 2003. PMID: 12767037 Review. - Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2.
Gallerne C, Prola A, Lemaire C. Gallerne C, et al. Biochim Biophys Acta. 2013 Jun;1833(6):1356-66. doi: 10.1016/j.bbamcr.2013.02.014. Epub 2013 Feb 26. Biochim Biophys Acta. 2013. PMID: 23485394 - Regulation of death receptors--relevance in cancer therapies.
de Thonel A, Eriksson JE. de Thonel A, et al. Toxicol Appl Pharmacol. 2005 Sep 1;207(2 Suppl):123-32. doi: 10.1016/j.taap.2005.03.032. Toxicol Appl Pharmacol. 2005. PMID: 16126242 Review. - Positive and negative regulation of apoptotic pathways by cytotoxic agents in hematological malignancies.
Solary E, Droin N, Bettaieb A, Corcos L, Dimanche-Boitrel MT, Garrido C. Solary E, et al. Leukemia. 2000 Oct;14(10):1833-49. doi: 10.1038/sj.leu.2401902. Leukemia. 2000. PMID: 11021759 Review.
Cited by
- Cyanidin-3-o-glucoside directly binds to ERα36 and inhibits EGFR-positive triple-negative breast cancer.
Wang L, Li H, Yang S, Ma W, Liu M, Guo S, Zhan J, Zhang H, Tsang SY, Zhang Z, Wang Z, Li X, Guo YD, Li X. Wang L, et al. Oncotarget. 2016 Oct 18;7(42):68864-68882. doi: 10.18632/oncotarget.12025. Oncotarget. 2016. PMID: 27655695 Free PMC article. - High temperature requirement A3 (HtrA3) promotes etoposide- and cisplatin-induced cytotoxicity in lung cancer cell lines.
Beleford D, Rattan R, Chien J, Shridhar V. Beleford D, et al. J Biol Chem. 2010 Apr 16;285(16):12011-27. doi: 10.1074/jbc.M109.097790. Epub 2010 Feb 12. J Biol Chem. 2010. PMID: 20154083 Free PMC article. - Nuclear medicine in the treatment of neuroendocrine tumours--problems and perspectives.
Grzela T, Bialoszewska A, Brawura-Biskupski-Samaha R. Grzela T, et al. Eur J Nucl Med Mol Imaging. 2007 Apr;34(4):444-7. doi: 10.1007/s00259-006-0300-6. Eur J Nucl Med Mol Imaging. 2007. PMID: 17136539 No abstract available. - P53/PUMA are potential targets that mediate the protection of brain-derived neurotrophic factor (BDNF)/TrkB from etoposide-induced cell death in neuroblastoma (NB).
Hua Z, Zhan Y, Zhang S, Dong Y, Jiang M, Tan F, Liu Z, Thiele CJ, Li Z. Hua Z, et al. Apoptosis. 2018 Aug;23(7-8):408-419. doi: 10.1007/s10495-018-1467-6. Apoptosis. 2018. PMID: 29959561 Free PMC article. - Low-dose valproic acid enhances radiosensitivity of prostate cancer through acetylated p53-dependent modulation of mitochondrial membrane potential and apoptosis.
Chen X, Wong JY, Wong P, Radany EH. Chen X, et al. Mol Cancer Res. 2011 Apr;9(4):448-61. doi: 10.1158/1541-7786.MCR-10-0471. Epub 2011 Feb 8. Mol Cancer Res. 2011. PMID: 21303901 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials